{"protocolSection": {"identificationModule": {"nctId": "NCT00529529", "orgStudyIdInfo": {"id": "CQAB149B2338"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Safety of Indacaterol in Patients (\u2265 12 Years) With Moderate to Severe Persistent Asthma", "officialTitle": "A 26-week Treatment, Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study to Assess the Safety of Indacaterol (300 and 600 \u00b5g o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 \u00b5g b.i.d.) as an Active Control"}, "statusModule": {"statusVerifiedDate": "2011-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-09"}, "primaryCompletionDateStruct": {"date": "2008-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-09-12", "studyFirstSubmitQcDate": "2007-09-12", "studyFirstPostDateStruct": {"date": "2007-09-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-07-22", "resultsFirstSubmitQcDate": "2011-07-22", "resultsFirstPostDateStruct": {"date": "2011-08-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-08-25", "lastUpdatePostDateStruct": {"date": "2011-08-29", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study was designed to assess the safety of indacaterol (300 \u00b5g and 600 \u00b5g (2 x 300 \u03bcg capsules) once daily \\[od\\]), compared with salmeterol (50 \u03bcg twice a day \\[b.i.d.\\]), over 26 weeks, in patients with moderate to severe persistent asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthma", "QAB149", "indacaterol"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 805, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Indacaterol 300 \u03bcg", "type": "EXPERIMENTAL", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol 300 \u03bcg", "Drug: Placebo to indacaterol", "Drug: Placebo to salmeterol"]}, {"label": "Indacaterol 600 \u03bcg", "type": "EXPERIMENTAL", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol 300 \u03bcg", "Drug: Placebo to salmeterol"]}, {"label": "Salmeterol 50 \u03bcg", "type": "ACTIVE_COMPARATOR", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 07:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Salmeterol 50 \u03bcg", "Drug: Placebo to indacaterol"]}], "interventions": [{"type": "DRUG", "name": "Indacaterol 300 \u03bcg", "description": "Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).", "armGroupLabels": ["Indacaterol 300 \u03bcg", "Indacaterol 600 \u03bcg"]}, {"type": "DRUG", "name": "Salmeterol 50 \u03bcg", "description": "Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.", "armGroupLabels": ["Salmeterol 50 \u03bcg"]}, {"type": "DRUG", "name": "Placebo to indacaterol", "description": "Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).", "armGroupLabels": ["Indacaterol 300 \u03bcg", "Salmeterol 50 \u03bcg"]}, {"type": "DRUG", "name": "Placebo to salmeterol", "description": "Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.", "armGroupLabels": ["Indacaterol 300 \u03bcg", "Indacaterol 600 \u03bcg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Patients With at Least 1 Adverse Event During the 26 Weeks of the Study", "description": "Adverse events include asthma exacerbations. An asthma exacerbation was defined as a worsening of asthma as judged clinically significant by the physician, requiring treatment with rescue oral or intravenous (IV) corticosteroids. Asthma worsening that required treatment with inhaled or nebulized short-acting \u03b22-agonists or an increase in inhaled corticosteroids only was not considered an asthma exacerbation.", "timeFrame": "Baseline (Day 1) to end of study (Week 26)"}, {"measure": "Systolic Blood Pressure 1 Hour Post-dose at Day 1", "description": "Systolic blood pressure measurements (in millimeters of mercury, mmHg) were made 1 hour post-dose after the patient had rested in the sitting position for at least 10 minutes. Measurements were made using an inflatable cuff around the upper arm. The analysis included baseline systolic blood pressure and forced expiratory volume in 1 second (FEV1) pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Day 1"}, {"measure": "Systolic Blood Pressure 1 Hour Post-dose at Week 12", "description": "Systolic blood pressure measurements (in millimeters of mercury, mmHg) were made 1 hour post-dose after the patient had rested in the sitting position for at least 10 minutes. Measurements were made using an inflatable cuff around the upper arm. The analysis included baseline systolic blood pressure and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Week 12"}, {"measure": "Diastolic Blood Pressure 1 Hour Post-dose at Day 1", "description": "Diastolic blood pressure measurements (in millimeters of mercury, mmHg) were made 1 hour post-dose after the patient had rested in the sitting position for at least 10 minutes. Measurements were made using an inflatable cuff around the upper arm. Phase V Korotkoff sounds were used for determination of diastolic pressure. The analysis included baseline diastolic blood pressure and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Day 1"}, {"measure": "Diastolic Blood Pressure 1 Hour Post-dose at Week 12", "description": "Diastolic blood pressure measurements (in millimeters of mercury, mmHg) were made 1 hour post-dose after the patient had rested in the sitting position for at least 10 minutes. Measurements were made using an inflatable cuff around the upper arm. Phase V Korotkoff sounds were used for determination of diastolic pressure. The analysis included baseline diastolic blood pressure and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Week 12"}, {"measure": "Corrected QT (QTc) Interval Using Fridericia's Formula Measured 1 Hour Post-dose at Day 1", "description": "The QTc interval (in milliseconds, ms) is calculated from electrocardiogram (ECG) data collected 1 hour post-dose using Fridericia's formula: QTc = QT/RR\\^0.33. QTc is the interval between the Q and T waves corrected for heart rate and RR is the interval between two R waves. ECGs included all 12 standard leads and a Lead II rhythm strip of at least 10-second duration. All results were sent to a central laboratory for review by a cardiologist. The analysis included baseline QTc interval and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Day 1"}, {"measure": "Corrected QT (QTc) Interval Using Fridericia's Formula Measured 1 Hour Post-dose at Week 12", "description": "The QTc interval (in milliseconds, ms) is calculated from electrocardiogram (ECG) data collected 1 hour post-dose using Fridericia's formula: QTc = QT/RR\\^0.33. QTc is the interval between the Q and T waves corrected for heart rate and RR is the interval between two R waves. ECGs included all 12 standard leads and a Lead II rhythm strip of at least 10-second duration. All results were sent to a central laboratory for review by a cardiologist. The analysis included baseline QTc interval and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Week 12"}, {"measure": "Corrected QT (QTc) Interval Using Fridericia's Formula Measured 1 Hour Post-dose at Week 21", "description": "The QTc interval (in milliseconds, ms) is calculated from electrocardiogram (ECG) data collected 1 hour post-dose using Fridericia's formula: QTc = QT/RR\\^0.33. QTc is the interval between the Q and T waves corrected for heart rate and RR is the interval between two R waves. ECGs included all 12 standard leads and a Lead II rhythm strip of at least 10-second duration. All results were sent to a central laboratory for review by a cardiologist. The analysis included baseline QTc interval and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Week 21"}, {"measure": "24 Hour Mean Heart Rate Determined From ECG Holter Monitoring at Week 12", "description": "Continuous 24 hour electrocardiography (Holter monitoring) was conducted in a subset of patients at designated study centers, and was used to calculate the mean heart rate (in beats per minute, bpm). Patients returned the Holter monitor recorder to the clinic the morning after the 24 hour recording was complete. The results of Holter monitoring were processed centrally. The analysis included baseline 24 hour mean heart rate and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Week 12"}, {"measure": "24 Hour Mean Heart Rate Determined From ECG Holter Monitoring at Week 26", "description": "Continuous 24 hour electrocardiography (Holter monitoring) was conducted in a subset of patients at designated study centers, and was used to calculate the mean heart rate (in beats per minute, bpm). Patients returned the Holter monitor recorder to the clinic the morning after the 24 hour recording was complete. The results of Holter monitoring were processed centrally. The analysis included baseline 24 hour mean heart rate and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Week 26"}, {"measure": "Serum Potassium 1 Hour Post-dose at Day 1", "description": "Serum potassium (in millimoles per liter, mmol/L) was measured from venous blood samples. Samples were sent to a central laboratory for analysis. The analysis included baseline serum potassium and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Day 1"}, {"measure": "Serum Potassium 1 Hour Post-dose at Week 12", "description": "Serum potassium (in millimoles per liter, mmol/L) was measured from venous blood samples. Samples were sent to a central laboratory for analysis. The analysis included baseline serum potassium and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Week 12"}, {"measure": "Blood Glucose 1 Hour Post-dose at Day 1", "description": "Blood glucose (in millimoles per liter, mmol/L) was measured from venous blood samples. Samples were sent to a central laboratory for analysis. The analysis included baseline blood glucose and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Day 1"}, {"measure": "Blood Glucose 1 Hour Post-dose at Week 12", "description": "Blood glucose (in millimoles per liter, mmol/L) was measured from venous blood samples. Samples were sent to a central laboratory for analysis. The analysis included baseline blood glucose and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "timeFrame": "Week 12"}, {"measure": "Percentage of Patients With Clinically Significant Asthma Exacerbations During the 26 Weeks of the Study", "description": "A clinically significant asthma exacerbation was defined as a worsening of asthma as judged clinically significant by the physician, requiring treatment with systemic corticosteroids. This includes events recorded on the asthma exacerbation clinical report form (CRF) page and events recorded on the adverse events CRF page with \"asthma\" as a key word in the preferred term.", "timeFrame": "Baseline (Day 1) to end of study (Week 26)"}], "secondaryOutcomes": [{"measure": "Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at Week 12 + 1 Day, Day 85", "description": "FEV1 (in liters, L) was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at Week 12, Day 85. The analysis included baseline FEV1 and FEV1 pre-dose and 30 minutes post-dose of salbutamol during screening as covariates.", "timeFrame": "24 hours post-dose at Week 12 + 1 day, Day 85"}, {"measure": "Number of Asthma Exacerbations Per Patient (Without Imputation) During the 26 Weeks of the Study", "description": "An asthma exacerbation was defined as a worsening of asthma as judged clinically significant by the physician, requiring treatment with rescue oral or intravenous (IV) corticosteroids. The number of asthma exacerbations includes events recorded on the asthma exacerbation clinical report form (CRF) page and events recorded on the adverse events CRF page with \"asthma\" as a key word in the preferred term.", "timeFrame": "Baseline (Day 1) to end of study (Week 26)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Male and female patients aged \u2265 12 years (or \u2265 18 years depending upon regulatory and/or Institutional Review Board/Independent Ethics Committee/Research Ethics Board \\[IRB/IEC/REB\\] approval) who have signed an informed consent form.\n2. Patients with moderate to severe persistent asthma, diagnosed according to the Global Initiative for Asthma (GINA) guidelines (Updated 2006) and who additionally meet the following criteria:\n\n   * Patients who have used treatment with a bronchodilator, either regularly or on-demand, and who had used a daily dose of at least 100 \u03bcg beclomethasone dipropionate (or equivalent) for at least 1 month prior to screening.\n   * Patients whose forced expiratory volume in 1 second (FEV1) is \u2265 50% of the predicted normal value.\n   * Patients with documented (in the previous 6 months) or who demonstrate (prior to randomization) a \u2265 12% and at least 200 ml increase in FEV1, after inhaling 200 \u03bcg salbutamol.\n\nExclusion Criteria:\n\n1. Pregnant or nursing (lactating) women and women of child-bearing potential UNLESS they meet pre-specified definitions of post-menopausal or are using pre-specified acceptable methods of contraception.\n2. Patients who have used tobacco products within the 12 month period prior to screening, or who have a smoking history of greater than 10 pack years.\n3. Patients who suffer from chronic obstructive pulmonary disease (COPD) as diagnosed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (2006).\n4. Patients who have had emergency room treatment for an acute asthma attack in the 6 weeks prior to screening or who have been hospitalized for an acute asthma attack in the 6 months prior to screening, or at any time between screening and Week 1.\n5. Patients with diabetes Type I or those with uncontrolled diabetes Type II including patients with a history of blood glucose levels consistently outside the normal range or glycosylated hemoglobin (HbA1C) \\> 8.0% measured at screening.\n6. Patients who, in the judgment of the investigator or the responsible Novartis personnel, have a clinically significant condition or a clinically relevant laboratory abnormality that might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study.\n7. Patients with a history of long QT syndrome, or whose QTc interval (Bazett's formula) is prolonged to \\> 450 ms (males) or \\> 470 ms (females).\n8. Certain medications for asthma and allied conditions such as long-acting bronchodilators must not be used prior to screening and for a pre-specified minimum washout period.\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Novartis Investigator Site", "city": "Glendale", "state": "Arizona", "zip": "85306", "country": "United States", "geoPoint": {"lat": 33.53865, "lon": -112.18599}}, {"facility": "Novartis Investigator Site", "city": "Phoenix", "state": "Arizona", "zip": "85306", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Novartis Investigator Site", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Novartis Investigator Site", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Novartis Investigator Site", "city": "Long Beach", "state": "California", "zip": "90806", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Novartis Investigator Site", "city": "Long Beach", "state": "California", "zip": "90808", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Novartis Investigator Site", "city": "los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Novartis Investigator Site x 2 sites", "city": "Oakland", "state": "California", "zip": "94609", "country": "United States", "geoPoint": {"lat": 37.80437, "lon": -122.2708}}, {"facility": "Novartis Investigator Site", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Novartis Investigator Site", "city": "Palmdale", "state": "California", "zip": "93551", "country": "United States", "geoPoint": {"lat": 34.57943, "lon": -118.11646}}, {"facility": "Novartis Investigator Site", "city": "San diego", "state": "California", "zip": "92120", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Novartis Investigator Site", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Novartis Investigator Site", "city": "Walnut Creek", "state": "California", "zip": "94598", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Novartis Investigator Site", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novartis Investigator Site", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novartis Investigator Site", "city": "Englewood", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.64777, "lon": -104.98776}}, {"facility": "Novartis Investigator Site", "city": "Lakewood", "state": "Colorado", "zip": "80401", "country": "United States", "geoPoint": {"lat": 39.70471, "lon": -105.08137}}, {"facility": "Novartis Investigator Site", "city": "Brandon", "state": "Florida", "zip": "33511", "country": "United States", "geoPoint": {"lat": 27.9378, "lon": -82.28592}}, {"facility": "Novartis Investigator Site", "city": "Largo", "state": "Florida", "zip": "33770", "country": "United States", "geoPoint": {"lat": 27.90979, "lon": -82.78842}}, {"facility": "Novartis Investigator Site", "city": "Miami", "state": "Florida", "zip": "33143", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Novartis Investigator Site", "city": "Panama City", "state": "Florida", "zip": "32405", "country": "United States", "geoPoint": {"lat": 30.15946, "lon": -85.65983}}, {"facility": "Novartis Investigator Site", "city": "Pensacola", "state": "Florida", "zip": "32503", "country": "United States", "geoPoint": {"lat": 30.42131, "lon": -87.21691}}, {"facility": "Novartis Investigator Site x 2 sites", "city": "Pensacola", "state": "Florida", "zip": "32514", "country": "United States", "geoPoint": {"lat": 30.42131, "lon": -87.21691}}, {"facility": "Novartis Investigator Site", "city": "Tamarac", "state": "Florida", "zip": "33321", "country": "United States", "geoPoint": {"lat": 26.21286, "lon": -80.24977}}, {"facility": "Novartis Investigator Site", "city": "Albany", "state": "Georgia", "zip": "31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "Novartis Investigator Site", "city": "Stockbridge", "state": "Georgia", "zip": "30281", "country": "United States", "geoPoint": {"lat": 33.54428, "lon": -84.23381}}, {"facility": "Novartis Investigator Site", "city": "overland Park", "state": "Kansas", "zip": "66210", "country": "United States", "geoPoint": {"lat": 38.98223, "lon": -94.67079}}, {"facility": "Novartis Investigator Site", "city": "Overland Park", "state": "Kansas", "zip": "66215", "country": "United States", "geoPoint": {"lat": 38.98223, "lon": -94.67079}}, {"facility": "Novartis Investigator Site", "city": "Topeka", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"facility": "Novartis Investigator Site", "city": "Florence", "state": "Kentucky", "zip": "41017", "country": "United States", "geoPoint": {"lat": 38.99895, "lon": -84.62661}}, {"facility": "Novartis Investigator Site", "city": "Baltimore", "state": "Maryland", "zip": "21236", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Novartis Investigator Site", "city": "Wheaton", "state": "Maryland", "zip": "20902", "country": "United States", "geoPoint": {"lat": 39.03983, "lon": -77.05526}}, {"facility": "Novartis Investigator Site", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Novartis Investigator Site", "city": "Ann Arbor", "state": "Michigan", "zip": "48106", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "Novartis Investigator Site", "city": "Ypsilanti", "state": "Michigan", "zip": "48197", "country": "United States", "geoPoint": {"lat": 42.24115, "lon": -83.61299}}, {"facility": "Novartis Investigator Site", "city": "Springfield", "state": "Missouri", "zip": "65807", "country": "United States", "geoPoint": {"lat": 37.21533, "lon": -93.29824}}, {"facility": "Novartis Investigator Site", "city": "St louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigator Site", "city": "Omaha", "state": "Nebraska", "zip": "68130", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Novartis Investigator Site", "city": "Omaha", "state": "Nebraska", "zip": "68131", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Novartis Investigator Site", "city": "Northfield", "state": "New Jersey", "zip": "08225", "country": "United States", "geoPoint": {"lat": 39.37039, "lon": -74.55015}}, {"facility": "Novartis Investigator Site", "city": "Rockville Centre", "state": "New York", "zip": "11570", "country": "United States", "geoPoint": {"lat": 40.65871, "lon": -73.64124}}, {"facility": "Novartis Investigator Site", "city": "Charlotte", "state": "North Carolina", "zip": "28207", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Novartis Investigator Site", "city": "High Point", "state": "North Carolina", "zip": "27262", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "Novartis Investigator Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Novartis Investigator Site", "city": "Cincinnati", "state": "Ohio", "zip": "45252", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Novartis Investigator Site", "city": "Toledo", "state": "Ohio", "zip": "43617", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Novartis Investigator Site", "city": "Edmond", "state": "Oklahoma", "zip": "73003", "country": "United States", "geoPoint": {"lat": 35.65283, "lon": -97.4781}}, {"facility": "Novartis Investigator Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novartis Investigator Site", "city": "Greenville", "state": "South Carolina", "zip": "29615", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Novartis Investigator Site", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novartis Investigator site", "city": "Houston", "state": "Texas", "zip": "77024", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigator Site", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigator Site", "city": "Houston", "state": "Texas", "zip": "77054", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigator Site", "city": "Houston", "state": "Texas", "zip": "77070", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigator Site", "city": "Kirkland", "state": "Washington", "zip": "98034", "country": "United States", "geoPoint": {"lat": 47.68149, "lon": -122.20874}}, {"facility": "Novartis Investigator Site", "city": "Seattle", "state": "Washington", "zip": "98105", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Novartis Investigator Site", "city": "Buenos Aires", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigator Site", "city": "Cordoba", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Novartis Investigator Site", "city": "Rosario", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Novartis Investigator Site", "city": "San Miguel de Tucuman", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Novartis Investigator Site", "city": "Halifax", "country": "Canada", "geoPoint": {"lat": 44.64533, "lon": -63.57239}}, {"facility": "Novartis Investigator Site", "city": "London", "country": "Canada", "geoPoint": {"lat": 42.98339, "lon": -81.23304}}, {"facility": "Novartis Investigator Site", "city": "Mississauga", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "Novartis Investigator Site", "city": "Montreal", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Novartis Investigator Site", "city": "Ste-Foy", "country": "Canada", "geoPoint": {"lat": 46.75615, "lon": -71.29543}}, {"facility": "Novartis Investigator Site", "city": "Brno", "country": "Czech Republic", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Novartis Investigative Site", "city": "Praha", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Novartis Investigator Site", "city": "Praha", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Novartis Investigator Site", "city": "Brest cedex", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Novartis Investigator Site", "city": "Castelnau-le-Lez", "country": "France", "geoPoint": {"lat": 43.63333, "lon": 3.9}}, {"facility": "Novartis Investigator Site", "city": "Chauny", "country": "France", "geoPoint": {"lat": 49.61514, "lon": 3.21857}}, {"facility": "Novartis Investigator Site", "city": "Paris Cedex 14", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Novartis Investigator Site", "city": "Tarbes Cedex", "country": "France", "geoPoint": {"lat": 43.23333, "lon": 0.08333}}, {"facility": "Novartis Investigator Site", "city": "Vandoeuvre Les Nancy", "country": "France", "geoPoint": {"lat": 48.65, "lon": 6.18333}}, {"facility": "Novartis Investigator Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigator Site", "city": "Bochum", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "Novartis Investigator Site", "city": "Borstel", "country": "Germany", "geoPoint": {"lat": 52.67034, "lon": 8.96896}}, {"facility": "Novartis Investigator Site", "city": "Geesthacht", "country": "Germany", "geoPoint": {"lat": 53.43575, "lon": 10.3779}}, {"facility": "Novartis Investigator Site", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Novartis Investigator Site", "city": "Kiel", "country": "Germany", "geoPoint": {"lat": 54.32133, "lon": 10.13489}}, {"facility": "Novartis Investigator Site", "city": "Leipzig", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novartis Investigator Site", "city": "Luebeck", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Novartis Investigator Site", "city": "Mainz", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Novartis Investigator Site", "city": "Marburg", "country": "Germany", "geoPoint": {"lat": 50.80904, "lon": 8.77069}}, {"facility": "Novartis Investigator Site", "city": "Neumunster", "country": "Germany", "geoPoint": {"lat": 54.07477, "lon": 9.98195}}, {"facility": "Novartis Investigator Site", "city": "Neuss", "country": "Germany", "geoPoint": {"lat": 51.19807, "lon": 6.68504}}, {"facility": "Novartis Investigator Site", "city": "Schwetzingen", "country": "Germany", "geoPoint": {"lat": 49.38217, "lon": 8.5823}}, {"facility": "Novartis Investigator Site", "city": "Wiesloch", "country": "Germany", "geoPoint": {"lat": 49.29504, "lon": 8.69846}}, {"facility": "Novartis Investigator Site", "city": "Wittem", "country": "Germany"}, {"facility": "Novartis Investigator Site", "city": "Debrecen", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"facility": "Novartis Investigator Site", "city": "Nyiregyhaza", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"facility": "Novartis Investigator Site", "city": "Sopron", "country": "Hungary", "geoPoint": {"lat": 47.68501, "lon": 16.59049}}, {"facility": "Novartis Investigator Site", "city": "Szombathely", "country": "Hungary", "geoPoint": {"lat": 47.23088, "lon": 16.62155}}, {"facility": "Novartis Investigator Site", "city": "Tatabanya", "country": "Hungary", "geoPoint": {"lat": 47.58494, "lon": 18.39325}}, {"facility": "Novartis Investigator Site", "city": "Brescia", "country": "Italy", "geoPoint": {"lat": 45.53558, "lon": 10.21472}}, {"facility": "Novartis Investigator Site", "city": "Catania", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "Novartis Investigator Site", "city": "Modena", "country": "Italy", "geoPoint": {"lat": 44.64783, "lon": 10.92539}}, {"facility": "Novartis Investigator Site", "city": "Parma", "country": "Italy", "geoPoint": {"lat": 44.79935, "lon": 10.32618}}, {"facility": "Novartis Investigator Site", "city": "Pietra Ligure", "country": "Italy", "geoPoint": {"lat": 44.1492, "lon": 8.28206}}, {"facility": "Novartis Investigator Site", "city": "Pisa", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Novartis Investigator Site", "city": "Terni", "country": "Italy", "geoPoint": {"lat": 42.56335, "lon": 12.64329}}, {"facility": "Novartis Investigator Site", "city": "Torino", "country": "Italy", "geoPoint": {"lat": 45.07049, "lon": 7.68682}}, {"facility": "Novartis Investigator Site", "city": "Trieste", "country": "Italy", "geoPoint": {"lat": 45.64953, "lon": 13.77679}}, {"facility": "Novartis Investigator Site", "city": "Lima", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Novartis Investigator Site", "city": "Bardejov", "country": "Slovakia", "geoPoint": {"lat": 49.29175, "lon": 21.27271}}, {"facility": "Novartis Investigator Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Novartis Investigator Site", "city": "Kosice", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Novartis Investigator Site", "city": "Nitra", "country": "Slovakia", "geoPoint": {"lat": 48.30763, "lon": 18.08453}}, {"facility": "Novartis Investigator Site", "city": "Trencin", "country": "Slovakia", "geoPoint": {"lat": 48.89452, "lon": 18.04436}}, {"facility": "Novartis Investigator Site", "city": "Alicante", "country": "Spain", "geoPoint": {"lat": 38.34517, "lon": -0.48149}}, {"facility": "Novartis Investigator Site", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Novartis Investigator Site", "city": "Begonte", "country": "Spain", "geoPoint": {"lat": 43.15121, "lon": -7.68643}}, {"facility": "Novartis Investigator Site", "city": "Caceres", "country": "Spain", "geoPoint": {"lat": 39.47649, "lon": -6.37224}}, {"facility": "Novartis Investigator Site", "city": "C\u00e1diz", "country": "Spain", "geoPoint": {"lat": 36.52672, "lon": -6.2891}}, {"facility": "Novartis Investigator Site", "city": "Granollers", "country": "Spain", "geoPoint": {"lat": 41.60797, "lon": 2.28773}}, {"facility": "Novartis Investigative Site", "city": "Hospitalet de Llobregat", "country": "Spain", "geoPoint": {"lat": 41.35967, "lon": 2.10028}}, {"facility": "Novartis Investigator Site", "city": "Hostalets de Baleny\u00e0", "country": "Spain"}, {"facility": "Novartis Investigator Site", "city": "Illescas", "country": "Spain", "geoPoint": {"lat": 40.12213, "lon": -3.84704}}, {"facility": "Novartis Investigator Site", "city": "Matar\u00f3", "country": "Spain", "geoPoint": {"lat": 41.54211, "lon": 2.4445}}, {"facility": "Novartis Investigator Site", "city": "Oviedo", "country": "Spain", "geoPoint": {"lat": 43.36029, "lon": -5.84476}}, {"facility": "Novartis Investigator Site", "city": "Sevilla", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Novartis Investigator Site", "city": "Valencia", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Novartis Investigator Site", "city": "Ankara", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Novartis Investigative Site", "city": "Istanbul", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Novartis Investigator Site", "city": "Istanbul", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Novartis Investigator Site", "city": "Izmir", "country": "Turkey", "geoPoint": {"lat": 38.41273, "lon": 27.13838}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "FG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "FG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "268"}, {"groupId": "FG001", "numSubjects": "268"}, {"groupId": "FG002", "numSubjects": "269"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "225"}, {"groupId": "FG001", "numSubjects": "225"}, {"groupId": "FG002", "numSubjects": "238"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "43"}, {"groupId": "FG001", "numSubjects": "43"}, {"groupId": "FG002", "numSubjects": "31"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "Subject withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Abnormal test procedure result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "BG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "BG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "268"}, {"groupId": "BG001", "value": "268"}, {"groupId": "BG002", "value": "269"}, {"groupId": "BG003", "value": "805"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "43.5", "spread": "15.84"}, {"groupId": "BG001", "value": "44.5", "spread": "15.19"}, {"groupId": "BG002", "value": "42.5", "spread": "15.24"}, {"groupId": "BG003", "value": "43.5", "spread": "15.43"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "151"}, {"groupId": "BG001", "value": "175"}, {"groupId": "BG002", "value": "164"}, {"groupId": "BG003", "value": "490"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "117"}, {"groupId": "BG001", "value": "93"}, {"groupId": "BG002", "value": "105"}, {"groupId": "BG003", "value": "315"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Patients With at Least 1 Adverse Event During the 26 Weeks of the Study", "description": "Adverse events include asthma exacerbations. An asthma exacerbation was defined as a worsening of asthma as judged clinically significant by the physician, requiring treatment with rescue oral or intravenous (IV) corticosteroids. Asthma worsening that required treatment with inhaled or nebulized short-acting \u03b22-agonists or an increase in inhaled corticosteroids only was not considered an asthma exacerbation.", "populationDescription": "Safety population: All patients who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Baseline (Day 1) to end of study (Week 26)", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "268"}, {"groupId": "OG001", "value": "268"}, {"groupId": "OG002", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54.9"}, {"groupId": "OG001", "value": "66.4"}, {"groupId": "OG002", "value": "67.3"}]}]}]}, {"type": "PRIMARY", "title": "Systolic Blood Pressure 1 Hour Post-dose at Day 1", "description": "Systolic blood pressure measurements (in millimeters of mercury, mmHg) were made 1 hour post-dose after the patient had rested in the sitting position for at least 10 minutes. Measurements were made using an inflatable cuff around the upper arm. The analysis included baseline systolic blood pressure and forced expiratory volume in 1 second (FEV1) pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at Day 1 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "263"}, {"groupId": "OG001", "value": "264"}, {"groupId": "OG002", "value": "264"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "122.79", "spread": "0.605"}, {"groupId": "OG001", "value": "122.60", "spread": "0.605"}, {"groupId": "OG002", "value": "122.56", "spread": "0.606"}]}]}]}, {"type": "PRIMARY", "title": "Systolic Blood Pressure 1 Hour Post-dose at Week 12", "description": "Systolic blood pressure measurements (in millimeters of mercury, mmHg) were made 1 hour post-dose after the patient had rested in the sitting position for at least 10 minutes. Measurements were made using an inflatable cuff around the upper arm. The analysis included baseline systolic blood pressure and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at week 12 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "238"}, {"groupId": "OG001", "value": "237"}, {"groupId": "OG002", "value": "244"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "120.29", "spread": "0.802"}, {"groupId": "OG001", "value": "121.98", "spread": "0.809"}, {"groupId": "OG002", "value": "122.02", "spread": "0.801"}]}]}]}, {"type": "PRIMARY", "title": "Diastolic Blood Pressure 1 Hour Post-dose at Day 1", "description": "Diastolic blood pressure measurements (in millimeters of mercury, mmHg) were made 1 hour post-dose after the patient had rested in the sitting position for at least 10 minutes. Measurements were made using an inflatable cuff around the upper arm. Phase V Korotkoff sounds were used for determination of diastolic pressure. The analysis included baseline diastolic blood pressure and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at Day 1 were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "263"}, {"groupId": "OG001", "value": "264"}, {"groupId": "OG002", "value": "264"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "76.67", "spread": "0.484"}, {"groupId": "OG001", "value": "76.55", "spread": "0.484"}, {"groupId": "OG002", "value": "77.08", "spread": "0.485"}]}]}]}, {"type": "PRIMARY", "title": "Diastolic Blood Pressure 1 Hour Post-dose at Week 12", "description": "Diastolic blood pressure measurements (in millimeters of mercury, mmHg) were made 1 hour post-dose after the patient had rested in the sitting position for at least 10 minutes. Measurements were made using an inflatable cuff around the upper arm. Phase V Korotkoff sounds were used for determination of diastolic pressure. The analysis included baseline diastolic blood pressure and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at week 12 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "238"}, {"groupId": "OG001", "value": "237"}, {"groupId": "OG002", "value": "244"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "75.38", "spread": "0.576"}, {"groupId": "OG001", "value": "76.11", "spread": "0.580"}, {"groupId": "OG002", "value": "76.96", "spread": "0.575"}]}]}]}, {"type": "PRIMARY", "title": "Corrected QT (QTc) Interval Using Fridericia's Formula Measured 1 Hour Post-dose at Day 1", "description": "The QTc interval (in milliseconds, ms) is calculated from electrocardiogram (ECG) data collected 1 hour post-dose using Fridericia's formula: QTc = QT/RR\\^0.33. QTc is the interval between the Q and T waves corrected for heart rate and RR is the interval between two R waves. ECGs included all 12 standard leads and a Lead II rhythm strip of at least 10-second duration. All results were sent to a central laboratory for review by a cardiologist. The analysis included baseline QTc interval and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at Day 1 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ms", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "265"}, {"groupId": "OG001", "value": "265"}, {"groupId": "OG002", "value": "265"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "404.46", "spread": "0.706"}, {"groupId": "OG001", "value": "404.97", "spread": "0.704"}, {"groupId": "OG002", "value": "405.05", "spread": "0.706"}]}]}]}, {"type": "PRIMARY", "title": "Corrected QT (QTc) Interval Using Fridericia's Formula Measured 1 Hour Post-dose at Week 12", "description": "The QTc interval (in milliseconds, ms) is calculated from electrocardiogram (ECG) data collected 1 hour post-dose using Fridericia's formula: QTc = QT/RR\\^0.33. QTc is the interval between the Q and T waves corrected for heart rate and RR is the interval between two R waves. ECGs included all 12 standard leads and a Lead II rhythm strip of at least 10-second duration. All results were sent to a central laboratory for review by a cardiologist. The analysis included baseline QTc interval and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at week 12 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ms", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "238"}, {"groupId": "OG001", "value": "236"}, {"groupId": "OG002", "value": "242"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "404.93", "spread": "0.970"}, {"groupId": "OG001", "value": "407.78", "spread": "0.979"}, {"groupId": "OG002", "value": "406.98", "spread": "0.967"}]}]}]}, {"type": "PRIMARY", "title": "Corrected QT (QTc) Interval Using Fridericia's Formula Measured 1 Hour Post-dose at Week 21", "description": "The QTc interval (in milliseconds, ms) is calculated from electrocardiogram (ECG) data collected 1 hour post-dose using Fridericia's formula: QTc = QT/RR\\^0.33. QTc is the interval between the Q and T waves corrected for heart rate and RR is the interval between two R waves. ECGs included all 12 standard leads and a Lead II rhythm strip of at least 10-second duration. All results were sent to a central laboratory for review by a cardiologist. The analysis included baseline QTc interval and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at week 21 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ms", "timeFrame": "Week 21", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "227"}, {"groupId": "OG001", "value": "228"}, {"groupId": "OG002", "value": "237"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "406.41", "spread": "1.005"}, {"groupId": "OG001", "value": "407.49", "spread": "1.014"}, {"groupId": "OG002", "value": "407.23", "spread": "0.995"}]}]}]}, {"type": "PRIMARY", "title": "24 Hour Mean Heart Rate Determined From ECG Holter Monitoring at Week 12", "description": "Continuous 24 hour electrocardiography (Holter monitoring) was conducted in a subset of patients at designated study centers, and was used to calculate the mean heart rate (in beats per minute, bpm). Patients returned the Holter monitor recorder to the clinic the morning after the 24 hour recording was complete. The results of Holter monitoring were processed centrally. The analysis included baseline 24 hour mean heart rate and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at week 12 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "bpm", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "74"}, {"groupId": "OG001", "value": "75"}, {"groupId": "OG002", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "81.0", "spread": "1.10"}, {"groupId": "OG001", "value": "81.7", "spread": "1.11"}, {"groupId": "OG002", "value": "80.4", "spread": "1.05"}]}]}]}, {"type": "PRIMARY", "title": "24 Hour Mean Heart Rate Determined From ECG Holter Monitoring at Week 26", "description": "Continuous 24 hour electrocardiography (Holter monitoring) was conducted in a subset of patients at designated study centers, and was used to calculate the mean heart rate (in beats per minute, bpm). Patients returned the Holter monitor recorder to the clinic the morning after the 24 hour recording was complete. The results of Holter monitoring were processed centrally. The analysis included baseline 24 hour mean heart rate and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at week 26 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "bpm", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "63"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "79.4", "spread": "0.96"}, {"groupId": "OG001", "value": "81.0", "spread": "0.96"}, {"groupId": "OG002", "value": "79.2", "spread": "0.96"}]}]}]}, {"type": "PRIMARY", "title": "Serum Potassium 1 Hour Post-dose at Day 1", "description": "Serum potassium (in millimoles per liter, mmol/L) was measured from venous blood samples. Samples were sent to a central laboratory for analysis. The analysis included baseline serum potassium and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at Day 1 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "262"}, {"groupId": "OG002", "value": "257"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.30", "spread": "0.022"}, {"groupId": "OG001", "value": "4.24", "spread": "0.023"}, {"groupId": "OG002", "value": "4.32", "spread": "0.023"}]}]}]}, {"type": "PRIMARY", "title": "Serum Potassium 1 Hour Post-dose at Week 12", "description": "Serum potassium (in millimoles per liter, mmol/L) was measured from venous blood samples. Samples were sent to a central laboratory for analysis. The analysis included baseline serum potassium and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at week 12 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "235"}, {"groupId": "OG001", "value": "233"}, {"groupId": "OG002", "value": "241"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.31", "spread": "0.025"}, {"groupId": "OG001", "value": "4.29", "spread": "0.025"}, {"groupId": "OG002", "value": "4.33", "spread": "0.025"}]}]}]}, {"type": "PRIMARY", "title": "Blood Glucose 1 Hour Post-dose at Day 1", "description": "Blood glucose (in millimoles per liter, mmol/L) was measured from venous blood samples. Samples were sent to a central laboratory for analysis. The analysis included baseline blood glucose and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at Day 1 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Day 1", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "265"}, {"groupId": "OG002", "value": "258"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.24", "spread": "0.061"}, {"groupId": "OG001", "value": "5.45", "spread": "0.061"}, {"groupId": "OG002", "value": "5.21", "spread": "0.062"}]}]}]}, {"type": "PRIMARY", "title": "Blood Glucose 1 Hour Post-dose at Week 12", "description": "Blood glucose (in millimoles per liter, mmol/L) was measured from venous blood samples. Samples were sent to a central laboratory for analysis. The analysis included baseline blood glucose and FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening as covariates.", "populationDescription": "Safety population: All patients who received at least one dose of study drug. Participants with observations at week 12 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "235"}, {"groupId": "OG001", "value": "234"}, {"groupId": "OG002", "value": "241"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.27", "spread": "0.068"}, {"groupId": "OG001", "value": "5.38", "spread": "0.069"}, {"groupId": "OG002", "value": "5.23", "spread": "0.068"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Patients With Clinically Significant Asthma Exacerbations During the 26 Weeks of the Study", "description": "A clinically significant asthma exacerbation was defined as a worsening of asthma as judged clinically significant by the physician, requiring treatment with systemic corticosteroids. This includes events recorded on the asthma exacerbation clinical report form (CRF) page and events recorded on the adverse events CRF page with \"asthma\" as a key word in the preferred term.", "populationDescription": "Intent-to-treat (ITT) population: All randomized patients who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Baseline (Day 1) to end of study (Week 26)", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "268"}, {"groupId": "OG001", "value": "268"}, {"groupId": "OG002", "value": "269"}]}], "classes": [{"title": "0 exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.9"}, {"groupId": "OG001", "value": "89.9"}, {"groupId": "OG002", "value": "90.0"}]}]}, {"title": "1 exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.6"}, {"groupId": "OG001", "value": "9.3"}, {"groupId": "OG002", "value": "8.6"}]}]}, {"title": "2 exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7"}, {"groupId": "OG001", "value": "0.7"}, {"groupId": "OG002", "value": "1.5"}]}]}, {"title": "3 exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7"}, {"groupId": "OG001", "value": "0.0"}, {"groupId": "OG002", "value": "0.0"}]}]}]}, {"type": "SECONDARY", "title": "Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at Week 12 + 1 Day, Day 85", "description": "FEV1 (in liters, L) was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at Week 12, Day 85. The analysis included baseline FEV1 and FEV1 pre-dose and 30 minutes post-dose of salbutamol during screening as covariates.", "populationDescription": "Intent-to-treat (ITT) population: All randomized patients who received at least 1 dose of study drug. Participants with observations at Day 85 were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "24 hours post-dose at Week 12 + 1 day, Day 85", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "258"}, {"groupId": "OG001", "value": "255"}, {"groupId": "OG002", "value": "262"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.61", "spread": "0.023"}, {"groupId": "OG001", "value": "2.62", "spread": "0.023"}, {"groupId": "OG002", "value": "2.54", "spread": "0.023"}]}]}]}, {"type": "SECONDARY", "title": "Number of Asthma Exacerbations Per Patient (Without Imputation) During the 26 Weeks of the Study", "description": "An asthma exacerbation was defined as a worsening of asthma as judged clinically significant by the physician, requiring treatment with rescue oral or intravenous (IV) corticosteroids. The number of asthma exacerbations includes events recorded on the asthma exacerbation clinical report form (CRF) page and events recorded on the adverse events CRF page with \"asthma\" as a key word in the preferred term.", "populationDescription": "Intent-to-treat (ITT) population: All randomized patients who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Asthma exacerbations", "timeFrame": "Baseline (Day 1) to end of study (Week 26)", "groups": [{"id": "OG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "268"}, {"groupId": "OG001", "value": "268"}, {"groupId": "OG002", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "spread": "0.561"}, {"groupId": "OG001", "value": "0.19", "spread": "0.512"}, {"groupId": "OG002", "value": "0.19", "spread": "0.494"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Baseline to the end of the study (Week 26)", "description": "Safety population: All patients who received at least one dose of study drug.", "eventGroups": [{"id": "EG000", "title": "Indacaterol 300 \u03bcg", "description": "Patients received indacaterol 300 \u03bcg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 300 \u03bcg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "seriousNumAffected": 5, "seriousNumAtRisk": 268, "otherNumAffected": 86, "otherNumAtRisk": 268}, {"id": "EG001", "title": "Indacaterol 600 \u03bcg", "description": "Patients received indacaterol 600 \u03bcg (2 x 300 \u03bcg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 7:00 and 11:00 AM). In addition to indacaterol 600 \u03bcg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "seriousNumAffected": 11, "seriousNumAtRisk": 268, "otherNumAffected": 105, "otherNumAtRisk": 268}, {"id": "EG002", "title": "Salmeterol 50 \u03bcg", "description": "Patients received salmeterol 50 \u03bcg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 7:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 \u03bcg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting \u03b22-agonist salbutamol/albuterol was available for rescue use throughout the study.", "seriousNumAffected": 8, "seriousNumAtRisk": 269, "otherNumAffected": 101, "otherNumAtRisk": 269}], "seriousEvents": [{"term": "Splenic cyst", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 269}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Biliary colic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 269}]}, {"term": "Cholangitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 269}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 269}]}, {"term": "Food allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Abscess neck", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 269}]}, {"term": "Upper respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 269}]}, {"term": "Lumbar vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Multiple fractures", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Facial paresis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 269}]}, {"term": "Pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 269}]}, {"term": "Stress", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Analgesic asthma syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 269}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 269}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 269}]}, {"term": "Dermatitis allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 269}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 16, "numAtRisk": 269}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 26, "numAtRisk": 269}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 27, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 18, "numAtRisk": 269}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 20, "numAtRisk": 269}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 30, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 39, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 40, "numAtRisk": 269}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 268}, {"groupId": "EG001", "numAffected": 29, "numAtRisk": 268}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 269}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "relevance": "LOW"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}